Medication info
Sitagliptin and Metformin Extended-Release Tablets 100/1000 mg

Sitagliptin and Metformin Extended-Release Tablets 100/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›113.4mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
DongKook Pharmaceutical Co., Ltd.
Appearance
Light blue, oval-shaped, convex, extended-release film-coated tablets
Packaging
28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle
Approval status
Active

MFDS item code 202201961 · Approved 2022.05.11 · Insurance code 653405220

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes
Who takes it
Adults
Adult dose
The dose of this medication for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this medication should be taken with a meal once daily, preferably in the evening, and the dose should be increased gradually. Take 1 tablet of this medication 100/1000 mg extended-release tablet once daily. Patients taking this medication 50/500 mg extended-release tablet or 50/1000 mg extended-release tablet should take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug treatment who have difficulty achieving adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this medication is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medication (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - The recommended initial total daily dose of this medication for patients who cannot achieve adequate glycemic control with metformin monotherapy is sitagliptin 100 mg and their current dose of metformin. - Patients switching to this medication from concomitant sitagliptin and metformin therapy may start at their current doses of sitagliptin and metformin. - Patients taking immediate-release metformin at a current dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this medication 50/1000 mg extended-release tablet once daily. 3. Patients unable to achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medication is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. Increase the dose gradually to reduce gastrointestinal adverse reactions caused by metformin. When administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). Studies evaluating the safety and efficacy of switching patients previously treated with other oral glucose-lowering agents to this medication have not been conducted. Any change in the treatment regimen for type 2 diabetes may cause changes in glycemic control; caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medication may be used, with the following dosage adjustment, in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medication must be discontinued immediately. Patients with hepatic impairment This medication should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).

Ingredients

Manufacturer
DongKook Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes

View approved original text

This medication helps control blood sugar levels in patients with type 2 diabetes by acting together with sitagliptin and metformin. It is used as an adjunct to dietary and exercise therapy to effectively improve blood sugar levels.

How to take

Adult dose

The dose of this medication for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this medication should be taken with a meal once daily, preferably in the evening, and the dose should be increased gradually. Take 1 tablet of this medication 100/1000 mg extended-release tablet once daily. Patients taking this medication 50/500 mg extended-release tablet or 50/1000 mg extended-release tablet should take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug treatment who have difficulty achieving adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this medication is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medication (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - The recommended initial total daily dose of this medication for patients who cannot achieve adequate glycemic control with metformin monotherapy is sitagliptin 100 mg and their current dose of metformin. - Patients switching to this medication from concomitant sitagliptin and metformin therapy may start at their current doses of sitagliptin and metformin. - Patients taking immediate-release metformin at a current dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this medication 50/1000 mg extended-release tablet once daily. 3. Patients unable to achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medication is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. Increase the dose gradually to reduce gastrointestinal adverse reactions caused by metformin. When administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). Studies evaluating the safety and efficacy of switching patients previously treated with other oral glucose-lowering agents to this medication have not been conducted. Any change in the treatment regimen for type 2 diabetes may cause changes in glycemic control; caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medication may be used, with the following dosage adjustment, in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medication must be discontinued immediately. Patients with hepatic impairment This medication should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).

Precautions

This medication contains two ingredients: sitagliptin and metformin. First, sitagliptin can rarely cause serious allergic reactions, including anaphylaxis, angioedema, and skin disorders. If any of these symptoms occur, stop taking this medication immediately and consult a doctor. Also, sitagliptin may cause acute pancreatitis, so patients should be monitored carefully for symptoms such as abdominal pain or vomiting during treatment. Metformin can cause a rare but potentially fatal metabolic complication called lactic acidosis. Symptoms may manifest as nonspecific symptoms such as muscle pain, weakness, shortness of breath, and abdominal pain, so it is essential to inform a doctor immediately if these symptoms occur. Additionally, this medication should not be administered to patients with impaired kidney function, liver disorders, severe infections, or dehydration. This medication may need to be temporarily discontinued before and after certain tests or surgeries. Especially before and after tests using iodinated contrast media, kidney function needs to be checked before resuming administration. Regular monitoring of kidney function, blood tests, and vitamin B12 levels is essential during treatment. Excessive alcohol consumption should be avoided during treatment as it may increase the risk of lactic acidosis. There is a risk of hypoglycemia, so special attention should be paid to hypoglycemic symptoms, particularly when taking other antidiabetic medications such as insulin or sulfonylureas. Irregular meals, vigorous exercise, or nutritional imbalances can also increase the risk of hypoglycemia. If symptoms such as severe joint pain or skin blisters occur, inform a doctor immediately, and discontinuation of the medication may be necessary. This medication is not to be used in women who are pregnant or may become pregnant, nursing mothers, or children under 18 years old. The elderly should have their kidney function assessed prior to taking this medication as renal function may decrease and regular monitoring is required. In case of overdose, consult a healthcare provider immediately, and blood dialysis or other treatments may be necessary if required. This medication may interact with various other drugs, so it is important to inform the healthcare provider of any other medications being taken.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory tract infection
  • headache
  • nausea
Show 17 more
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • peripheral edema
  • severe and disabling arthralgia
  • bullous pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • rash
  • urticaria
  • cutaneous vasculitis
  • acute kidney failure

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly closed container to prevent air or moisture ingress, at a temperature between 1°C and 30°C. Proper storage helps maintain the medication’s effectiveness for a prolonged period.

Appearance and packaging

Appearance

Light blue, oval-shaped, convex, extended-release film-coated tablets

Package unit

28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.